Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
- Autori: Santini D; Barni S; Intagliata S; Falcone A; Ferraù F; Galetta D; Moscetti L; La Verde N; Ibrahim T; Petrelli F; Vasile E; Ginocchi L; Ottaviani D; Longo F, Ortega C; Russo A; Badalamenti G; Collovà E; Lanzetta G; Mansueto G; Adamo V; De Marinis F; Satolli MA; Cantile F; Mancuso A; Tanca FM; Addeo R; Russano M; Sterpi M; Pantano F; Vincenzi B; Tonini G.
- Anno di pubblicazione: 2015
- Tipologia: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/200704
We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.